Skip to main content
. Author manuscript; available in PMC: 2019 Jul 28.
Published in final edited form as: J Control Release. 2018 Apr 27;282:110–119. doi: 10.1016/j.jconrel.2018.04.045

Figure 4. Excipients are Biocompatible with HCAVSMCs.

Figure 4

HCAVSMCs were treated for two hours with MK2i-NP formulations or MK2i peptide alone at a dose of 100 uM and subsequently cultured in fresh medium for an additional 24 hours. Cell viability was then assessed through a lactate dehydrogenase (LDH) based cytotoxicity assay and normalized to untreated control cells (n = 3). NT = no treatment, Ctrl = excipient without polyplexes.